ATE368227T1 - Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können - Google Patents

Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können

Info

Publication number
ATE368227T1
ATE368227T1 AT00959571T AT00959571T ATE368227T1 AT E368227 T1 ATE368227 T1 AT E368227T1 AT 00959571 T AT00959571 T AT 00959571T AT 00959571 T AT00959571 T AT 00959571T AT E368227 T1 ATE368227 T1 AT E368227T1
Authority
AT
Austria
Prior art keywords
tgf
agents
screening
compounds
dependent cell
Prior art date
Application number
AT00959571T
Other languages
English (en)
Inventor
Merl Hoekstra
Weilin Xie
Brion Murray
Frank Mercurio
Original Assignee
Signal Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Inc filed Critical Signal Pharm Inc
Application granted granted Critical
Publication of ATE368227T1 publication Critical patent/ATE368227T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00959571T 1999-08-30 2000-08-29 Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können ATE368227T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/385,918 US7358056B1 (en) 1999-08-30 1999-08-30 Methods for modulating signal transduction mediated by TGF-β and related proteins

Publications (1)

Publication Number Publication Date
ATE368227T1 true ATE368227T1 (de) 2007-08-15

Family

ID=23523429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959571T ATE368227T1 (de) 1999-08-30 2000-08-29 Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können

Country Status (8)

Country Link
US (2) US7358056B1 (de)
EP (2) EP1212621B1 (de)
JP (1) JP2003508755A (de)
AT (1) ATE368227T1 (de)
AU (1) AU781152B2 (de)
CA (1) CA2383514A1 (de)
DE (1) DE60035697T2 (de)
WO (1) WO2001016604A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532981A (ja) * 2001-04-10 2004-10-28 チルドレンズ メディカル センター コーポレーション タンパク質−タンパク質相互作用の解析および標識の方法
EP1406678B1 (de) * 2001-04-25 2009-01-14 Eidgenössische Technische Hochschule Zürich Arzneimittel freisetzende matrizen zur förderung der wundheilung
US7253155B2 (en) * 2001-10-05 2007-08-07 Combinatorx, Inc. Combinations for the treatment of immunoinflammatory disorders
GB0302315D0 (en) * 2003-02-01 2003-03-05 Univ East Anglia Novel therapeutic target
DK2332977T3 (en) * 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
JP2010530217A (ja) 2007-05-29 2010-09-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 造骨活性及び破骨活性の調節に関与する分子、並びにその使用法
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
GB201013284D0 (en) * 2010-08-06 2010-09-22 Isogenica Ltd Scaffold peptides
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CN103558395B (zh) * 2013-10-28 2015-08-26 深圳市第二人民医院 Smad3基因在检测上尿路上皮癌中的应用
KR101683544B1 (ko) * 2014-12-19 2016-12-08 한양대학교 산학협력단 탈인산화 또는 인산화 효소 활성 검출용 조성물 및 검출 방법
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
AU2020275425B2 (en) * 2019-05-15 2024-06-27 Synthex, Inc. Selective degradation of proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001619A (en) 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
US6011137A (en) * 1996-04-03 2000-01-04 University Of North Carolina At Chapel Hill Identification and isolation of novel polypeptides having WW domains and methods of using same
US6103869A (en) 1997-05-20 2000-08-15 Ludwig Institute For Cancer Research Smad2 phosphorylation and interaction with Smad4
AU8281398A (en) 1997-07-01 1999-01-25 Sloan-Kettering Institute For Cancer Research Methods of inhibiting or enhancing the tgfbeta-smad signaling pathway
US6060262A (en) 1997-07-16 2000-05-09 Mitotix, Inc. Regulation of I Kappa B (IκB) degradation and methods and reagents related thereto
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
CA2376675A1 (en) 1999-06-11 2000-12-21 The Research Foundation Of State University Of New York Antagonists of bmp and tgf.beta. signalling pathways

Also Published As

Publication number Publication date
EP1212621A1 (de) 2002-06-12
EP1212621B1 (de) 2007-07-25
CA2383514A1 (en) 2001-03-08
US20030119072A1 (en) 2003-06-26
AU781152B2 (en) 2005-05-12
EP1918716A2 (de) 2008-05-07
DE60035697D1 (de) 2007-09-06
JP2003508755A (ja) 2003-03-04
US7358056B1 (en) 2008-04-15
DE60035697T2 (de) 2008-04-30
WO2001016604A1 (en) 2001-03-08
AU7086600A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
ATE368227T1 (de) Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
PT934325E (pt) Trisanidridos biciclicos de tetrafosfonato
ATE337021T1 (de) Anordnungen, systeme und verfahren zur behandlung von biologischen flüssigkeiten mit licht
ATE353640T1 (de) Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
DE59709515D1 (de) Verfahren zur herstellung von wirkstoffhaltigen knochenzementen
BR8802492A (pt) Composicao esterilizante e de alto grau desinfetante,inodora
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
DE60029812D1 (de) Diagnose von zellenproliferation sowie screeningverfahren für deren modulatore
DK1113810T3 (da) Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
DE69630955T2 (de) Immortalisierung bzw. desimmortalisierung von zellen
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE69013999D1 (de) Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
DE69425820D1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
YU41998A (sh) Tetrahidrobetakarbolinska jedinjenja
DE60112742D1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE259818T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
DE60042210D1 (de) Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE60000658D1 (de) Zusammensetzung zur behandlung von psoriasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties